Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBAOTCMKTS:CSLLYNYSE:GSKNYSE:GSK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$2.42+0.2%$1.98$0.80▼$2.89$570.50M0.872.79 million shs1.37 million shsCSLLYCSL$80.36+2.6%$78.73$70.22▼$109.00$77.82B0.896,040 shs54,853 shsGSKGSK$39.03-2.1%$37.64$31.72▼$45.93$80.54B0.564.74 million shs2.42 million shsGSKGSK$39.03-2.1%$37.64$31.72▼$45.93$80.54B0.564.74 million shs2.42 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics-0.82%+11.57%+25.52%+4.78%+91.27%CSLLYCSL+2.57%+4.80%+1.63%-7.81%-10.31%GSKGSK+1.79%+7.55%+2.62%+12.66%-3.86%GSKGSK+1.79%+7.55%+2.62%+12.66%-3.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics4.0828 of 5 stars4.61.00.04.02.20.80.6CSLLYCSL1.0688 of 5 stars0.03.01.70.01.80.01.3GSKGSK1.2348 of 5 stars1.23.02.50.02.00.01.3GSKGSK1.2348 of 5 stars1.23.02.50.02.00.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.20Buy$6.63174.33% UpsideCSLLYCSL 4.00Strong BuyN/AN/AGSKGSK 2.42Hold$40.583.99% UpsideGSKGSK 2.42Hold$40.583.99% UpsideCurrent Analyst Ratings BreakdownLatest AKBA, CSLLY, GSK, and GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025AKBAAkebia TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025AKBAAkebia TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$7.004/28/2025GSKGSKHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell4/28/2025GSKGSKHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell4/15/2025GSKGSKBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$35.254/15/2025GSKGSKBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$35.254/4/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.504/1/2025AKBAAkebia TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.003/14/2025AKBAAkebia TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$4.00 ➝ $6.003/14/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.502/12/2025GSKGSKMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$160.18M3.56N/AN/A($0.16) per share-15.09CSLLYCSL$14.80B5.26$3.86 per share20.80$20.07 per share4.00GSKGSK$31.38B2.57$6.18 per share6.32$8.07 per share4.84GSKGSK$31.38B2.57$6.18 per share6.32$8.07 per share4.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$51.92M-$0.33N/AN/AN/A-27.07%N/A-20.57%5/8/2025 (Estimated)CSLLYCSL$2.64BN/A0.0019.651.59N/AN/AN/AN/AGSKGSK$3.29B$1.5924.558.391.128.13%48.59%11.11%N/AGSKGSK$3.29B$1.5924.558.391.128.13%48.59%11.11%N/ALatest AKBA, CSLLY, GSK, and GSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025AKBAAkebia Therapeutics-$0.03N/AN/AN/A$44.88 millionN/A4/30/2025Q1 2025GSKGSK$1.08$1.13+$0.05$1.00$7.52 billion$10.06 billion4/30/2025Q1 2025GSKGSK$1.08$1.13+$0.05$1.00$7.52 billion$10.06 billion3/13/2025Q4 2024AKBAAkebia Therapeutics-$0.05-$0.10-$0.05-$0.10$37.36 million$46.50 million2/5/2025Q4 2024GSKGSK$0.44$0.59+$0.15$0.26$7.75 billionN/A2/5/2025Q4 2024GSKGSK$0.44$0.59+$0.15$0.26$7.75 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/ACSLLYCSL$1.201.49%N/AN/AN/AGSKGSK$1.604.10%-17.33%100.63%N/AGSKGSK$1.604.10%-17.33%100.63%N/ALatest AKBA, CSLLY, GSK, and GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/5/2025GSKGSKquarterly$0.39324.2%2/21/20252/21/20254/10/20252/5/2025GSKGSKquarterly$0.39324.2%2/21/20252/21/20254/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia TherapeuticsN/A1.521.21CSLLYCSL0.582.180.97GSKGSK1.120.780.52GSKGSK1.120.780.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%CSLLYCSL0.03%GSKGSK15.74%GSKGSK15.74%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics4.10%CSLLYCSLN/AGSKGSK10.00%GSKGSK10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430236.23 million209.24 millionOptionableCSLLYCSL30,000968.42 millionN/ANot OptionableGSKGSK90,1002.06 billion1.87 billionOptionableGSKGSK90,1002.06 billion1.87 billionOptionableAKBA, CSLLY, GSK, and GSK HeadlinesRecent News About These CompaniesGSK sets up Nucala and Dupixent showdown in COPDMay 1 at 1:18 PM | pharmaphorum.comGSK PLC (GSK) Q1 2025 Earnings Call Highlights: Strong Specialty Medicines Growth Amid Vaccine ...May 1 at 1:18 PM | finance.yahoo.comHere's Why GSK (GSK) is a Strong Growth StockMay 1 at 10:46 AM | zacks.comQ1 2025 GSK plc Earnings Call TranscriptMay 1 at 8:18 AM | gurufocus.comGSK's Nucala delivers positive outcomes in published trial resultsMay 1 at 8:17 AM | sharecast.comAltesa Bio Hires Former GSK Official for Antiviral Drug DevelopmentMay 1 at 8:17 AM | wsj.comGSK remains resilient on tariffs as Q1 sales rise 4%May 1 at 8:17 AM | finance.yahoo.comGSK plc (NYSE:GSK) Shares Purchased by Schonfeld Strategic Advisors LLCMay 1 at 8:12 AM | marketbeat.comAs the GSK share price bounces back, Q1 results raise hopes for more to comeMay 1 at 3:16 AM | uk.finance.yahoo.comGSK turns to AI to offset potential US tariff hitApril 30 at 10:15 PM | ft.comGSK Jumps On Solid Earnings, Says It's 'Well Positioned' To Navigate TariffsApril 30 at 10:15 PM | msn.comGSK (LSE:GSK) Sees First Quarter Sales of £7.5 Billion and Net Income SurgeApril 30 at 5:14 PM | finance.yahoo.comAs vaccine sales slip, GSK touts 'mitigation options' for potential drug tariffsApril 30 at 5:14 PM | fiercepharma.comEuropeans must do more to boost pharma or risk losing jobs and investment to the US, warns GSK bossApril 30 at 5:14 PM | thisismoney.co.ukGSK Optimistic About M&A Prospects Despite Trump Tariff ThreatsApril 30 at 5:14 PM | biospace.comGSK posts Q1 beat thanks to Specialty MedicinesApril 30 at 5:14 PM | msn.comGSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff ReassuranceApril 30 at 12:46 PM | zacks.comGSK plc (GSK) Q1 2025 Earnings Conference Call TranscriptApril 30 at 12:32 PM | seekingalpha.comHere's Why GSK (GSK) is a Strong Momentum StockApril 30 at 10:55 AM | zacks.comBritain's GSK Asserts It Is 'Well Positioned' To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug SalesApril 30 at 10:02 AM | benzinga.comCervarix Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts | GSK Leads Cervarix Market Amid Global Vaccination EffortsApril 30 at 9:41 AM | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKBA, CSLLY, GSK, and GSK Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$2.42 +0.01 (+0.21%) As of 01:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.CSL OTCMKTS:CSLLY$80.36 +2.01 (+2.57%) As of 04/30/2025 03:59 PM EasternCSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.GSK NYSE:GSK$39.03 -0.82 (-2.06%) As of 01:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.GSK NYSE:GSK$39.03 -0.82 (-2.06%) As of 01:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
